Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma

Authors

Toni K. Choueiri, Harvard University
James J. Hsieh, Washington University School of Medicine in St. Louis
et al

Journal

The New England Journal of Medicine

Publication Date

2021

Volume

384

Issue

9

First Page

829

Last Page

841

Document Type

Open Access Publication

DOI

10.1056/NEJMoa2026982

Rights and Permissions

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982

Recommended Citation

Choueiri, Toni K.; Hsieh, James J.; and al, et, "Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma." The New England Journal of Medicine. 384, 9. 829 - 841. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10691